Operational Handbooks
5.1 Introduction
This chapter summarizes the treatment options available for children and adolescents to treat drug-susceptible TB and DR-TB and pulmonary and extrapulmonary forms of TB (including TBM), and considerations related to post-TB health. It includes operational guidance on various new treatment approaches, including a 4-month treatment regimen, and important implementation considerations such as availability of child-friendly formulations and access to all key medicines for the treatment of DR-TB.
3.3.5.2. Dosages
The WHO task force on pharmacokinetics and pharmacodynamics analysed available evidence from clinical trials of rifapentine and suggested a simplified dose for various weight bands for 3HP and 1HP for the 2020 WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment (28). Table 3.2 presents standard dosing for the recommended TPT regimens by age and body weight.
Table 3.2. Dosing for recommended TB preventive treatment regimens
Annex 7. Overview of options for neurocognitive and functional testing at end of treatment for TB meningitis
Table A7.1. Options for neurocognitive and functional testing at end of treatment for TB meningitis
Annex 5. Treatment decision algorithms
Methodology for developing the treatment decision algorithms
Pagination
- Previous page
- Page 56
- Next page